RT Journal Article
T1 Linezolid for infective endocarditis A structured approach based on a national database experience
A1 Munoz, P.
A1 De la Villa, S.
A1 Martinez-Selles, M.
A1 Goenaga, M. A.
A1 Reviejo-Jaka, K.
A1 Arnaiz de las Revillas, F.
A1 Garcia-Cuello, L.
A1 Hidalgo-Tenorio, C.
A1 Rodriguez-Esteban, M. A.
A1 Antorrena, I
A1 Castelo-Corral, L.
A1 Garcia-Vazquez, E.
A1 De la Torre, J.
A1 Bouza, E.
A1 Spanish Collaboration Endocarditis, 
A1 Grp Apoyo Manejo Endocarditis Infe, 
K1 Enterococcus
K1 infective endocarditis
K1 linezolid
K1 mortality
K1 Staphylococcus
K1 Complicated skin
K1 Resistant
K1 Therapy
K1 Vancomycin
K1 Management
K1 Bacteremia
K1 Diagnosis
K1 Efficacy
AB Current data on the frequency and efficacy of linezolid (LNZ) in infective endocarditis (IE) are based on small retrospective series. We used a national database to evaluate the effectiveness of LNZ in IE. This is a retrospective study of IE patients in the Spanish GAMES database who received LNZ. We defined 3 levels of therapeutic impact: LNZ = 7 days, > 50% of the total treatment, and > 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ >= 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses. From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ  50% of the total treatment, and > 50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ >= 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses. From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ  50% of the LNZ doses prescribed in the first weeks of treatment), and LNZ >= 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses. From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ = 7 days not fulfilling the high-impact criteria (LNZ-NHI). Effectiveness of LNZ was assessed using propensity score matching and multivariate analysis of high-impact cases in comparison to patients not treated with LNZ from the GAMES database matched for age-adjusted comorbidity Charlson index, heart failure, renal failure, prosthetic and intracardiac IE device, left-sided IE, and Staphylococcus aureus. Primary outcomes were in-hospital mortality and one-year mortality. Secondary outcomes included IE complications and relapses. From 3467 patients included in the GAMES database, 295 (8.5%) received LNZ. After excluding 3 patients, 292 were grouped as follows for the analyses: 99 (33.9%) patients in LNZ
PB Lippincott williams & wilkins
SN 0025-7974
YR 2021
FD 2021-12-23
LK https://hdl.handle.net/10668/26477
UL https://hdl.handle.net/10668/26477
LA en
DS RISalud
RD Apr 7, 2025